Drug search by name

Adriamycin and Cardioxane Injection

Determining the interaction of Adriamycin and Cardioxane Injection and the possibility of their joint administration.

Check result:

Adriamycin <> Cardioxane Injection

Relevance: 20.09.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

When dexrazoxane is used to reduce the risk and severity of cardiac side effects associated with DOXOrubicin therapy, it is important that these medications not be started at the same time because doing so may reduce the effectiveness of DOXOrubicin in treating your cancer. In general, dexrazoxane is not indicated until after you have received a certain amount of DOXOrubicin and will continue to receive DOXOrubicin beyond that point. Talk to your doctor or pharmacist if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

ADJUST DOSING INTERVAL: Coadministration with dexrazoxane may diminish the therapeutic response to doxorubicin. Since both are topoisomerase inhibitors, it is possible that dexrazoxane may interfere with the anti-tumor effects of doxorubicin. In a randomized clinical study of women with metastatic breast cancer, initiation of dexrazoxane with doxorubicin-based chemotherapy resulted in a significantly lower tumor response rate (48% vs. 63%) and shorter time to progression than doxorubicin-based chemotherapy plus placebo.

MANAGEMENT: When used as a cardioprotectant, dexrazoxane should not be administered at the initiation of doxorubicin-containing chemotherapy regimens. Dexrazoxane is indicated for reduction of the risk and severity of doxorubicin-induced cardiomyopathy in patients who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin.

References

Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
"Product Information. Zinecard (dexrazoxane)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
Swain SM, Whaley FS, Gerber MC, et al. "Cardioprotection with dexrazoxane for doxorubicin- containing therapy in advanced breast cancer." J Clin Oncol 15 (1997): 1318-32
"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.

Adriamycin

Generic Name: doxorubicin

Brand name: Adriamycin, Adriamycin RDF, Rubex, Adriamycin PFS

Synonyms: n.a.

What is Adriamycin?

Cardioxane Injection

Generic Name: dexrazoxane

Brand name: Totect, Zinecard

Synonyms: Dexrazoxane

What is Cardioxane Injection?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions